XL-888 is under clinical development by Exelixis and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect XL-888’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 31 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their XL-888 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

XL-888 overview

XL-888 is under development for the treatment of melanoma, gastroesophageal junction adenocarcinoma, small intestinal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma and gastric cancer. It is a small molecule administered orally. It targets heat shock protein 90 (HSP90). It was also under development for the treatment of solid tumor.

Exelixis overview

Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include XL092 for the treatment of advanced solid malignancies and XL888, an ATP-competitive inhibitor of HSP90, and others. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.

Quick View XL-888 LOA Data

Report Segments
  • Innovator
Drug Name
  • XL-888
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.